The 3 most recent market catalysts affecting $NVGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 60
NervGen Pharma Appoints Sam Jackson, MD, MBA, as Chief Medical Officer
NervGen Pharma has appointed Dr. Sam Jackson as Chief Medical Officer, a significant move as the company progresses its lead neuroreparative candidate, NVG-291, through a crucial P…
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 75
NervGen Pharma Reports Q3 2026 Financial Results and Business Updates
NervGen Pharma's Q3 2026 earnings report provides an update on its key clinical asset, NVG-291, which is in a Phase 3 trial for chronic spinal cord injury. The announcement of an F…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 92
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
NervGen Pharma Corp. announced that its drug candidate, NVG-291, received FDA Breakthrough Therapy designation for chronic spinal cord injury. This is a significant event because B…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.